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Background: Vascular smooth muscle cell (SMC) migration is an important component of the development of intimal
hyperplasia. Sphingosine-1-phosphate (S-1-P) is a lipid released from activated platelets with numerous cellular effects
including the stimulation of SMC migration in vitro. We examined the role of the mammalian target of rapamycin and
ribosomal p70S6 kinase (p70S6K) in S-1-P–induced SMC migration.
Methods: Rat arterial SMCs were cultured in vitro. Linear wound and Boyden microchemotaxis assays of migration were
performed in the presence of S-1-P (0.01 to 100 mol/L) with and without rapamycin (10 nmol/L). Western blotting
was performed for phosphorylated and total p70S6K, ERK1/2, and p38MAPK after stimulation with S-1-P (0.1
mol/L), with and without rapamycin pretreatment. Phosphorylation of p70S6K was also assayed after S-1-P treatment
in the presence and absence of inhibitors of PI3 kinase (wortmannin, WN, and LY294002, LY), Akt (AktI), p38MAPK
(SB203580), and MEK1 (PD98059).
Results: S-1-P stimulated migration of SMCs in both linear wound and Boyden chamber assays compared to control
(P < .05); these responses were inhibited by rapamycin to below the level of control (P < .05 vs S-1-P alone for both
assays) in a dose-dependent manner (inhibitory concentration of 50%, 10 nmol/L). S-1-P stimulated phosphorylation of
ERK1/2, p38MAPK, and p70S6K, which peaked at 5 minutes for ERK1/2 and p38MAPK and10 minutes for p70S6K
(2-fold increase over control for each, P< .05). Rapamycin prevented the phosphorylation of p70S6K at the Thr 389 site
(which correlates with enzyme activity), reduced ERK1/2 phosphorylation, but had no effect on the Thr 421/Ser 424
site or on p38MAPK phosphorylation. Wortmannin and LY294002 inhibited phosphorylation of the Thr 389 site of
p70S6K. AktI and SB203580 had no effect on p70S6K, whereas PD98059 had a marginal effect.
Conclusions: S-1-P–induced SMC migration was completely inhibited by rapamycin, indicating that the p70S6K pathway
is involved. This mechanism likely involves modulation of the ERK1/2 pathway. S-1-P stimulates phosphorylation of
p70S6K in a MEK1-dependent, PI3 kinase–dependent, but Akt-independent manner. (J Vasc Surg 2005;41:91-8.)
Clinical Relevance: S-1-P is released from activated platelets at sites of vessel injury and contributes to the development
of intimal hyperplasia after bypass grafting, angioplasty, and stenting. S-1-P is a potent pro-migratory molecule for
SMCs. Rapamycin is a commonly used immunosuppressive agent that has most recently been incorporated as the biologic
agent in drug eluting stents with good success in the coronary circulation. Rapamycin inhibits the mammalian target of
rapamycin, which, in turn, controls the translational mechanisms of the cell. The role of translational control during
S-1-P–induced SMC migration is poorly understood. This study identifies a link between the mammalian target of
rapamycin translational pathway and S-1-P and demonstrates how rapamycin might interfere with another facet of a
vessel’s response to injury after a vascular intervention, namely by interfering with the cell signaling of factors released
from platelets deposited at the injury site.Sphingosine-1-phosphate (S-1-P) is a bioactive sphin-
golipid found in human plasma and serum1 and is released
in large amounts from activated platelets (reaching micro-
molar concentrations in serum).2 As a factor released from
activated platelets at sites of vessel injury, S-1-P might
regulate vascular smooth muscle cell (SMC) migration after
endothelial injury. Previous data from our group suggest
that S-1-P is a moderate chemoattractant for SMCs ex-
pressing S-1-P receptors (types 1, 2, and 3)3,4; others have
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the coronary circulation. Rapamycin inhibits the mamma-
lian target of rapamycin (mTOR), which in turn controls
the kinase p70S6 (p70S6K) and translational mechanisms
of the cell.7 This report seeks to determine the role of
mTOR in migration of rat aortic SMCs that naturally
express a considerable amount of S1P1 and to determine
the upstream regulation of p70S6K after S-1-P stimulation.
METHODS
Materials. D-erythro-sphingosine-1-phosphate was
purchased from Avanti Polar-Lipids (Alabaster, Ala). Poly-
clonal antibodies to phospho-p70S6K (both threonine
421/serine 424 and threonine 389 sites) and total p70S6K
were purchased from Cell Signaling Technology (Beverly,
Mass). Phospho-ERK1/2 antibody was purchased from
Promega, Inc (Madison, Wis). Total ERK1/2 antibody
was purchased from BD Transduction Laboratories (Lex-
ington, Ky). Peroxidase-conjugated anti-rabbit immuno-
globulin G antibody (raised in goat) was purchased from
Jackson ImmunoResearch Laboratories, Inc (West Grove,
Pa). Peroxidase-conjugated anti-mouse immunoglobulin
G antibody (raised in goat) was purchased from Biorad
Laboratories (Hercules, Calif). Rapamycin, Akt inhibitors
(AktI-1, AktI-2, and AktI-3) and PD98059 were pur-
chased from Calbiochem (La Jolla, Calif). Wortmannin,
SB203580, and pertussis toxin were purchased from Sigma
Chemical Co (St Louis, Mo). LY294002 was purchased
from Biomol (Plymouth Meeting, Pa).
Cell culture. Primary rat aortic thoracic SMCs (male
Sprague-Dawley, VSMC) in passages 10 to 20 were used.
Cultured cells were kept in 100-mm2 dishes in 6 mL
Dulbecco modified Eagle medium (DMEM)/10% fetal
bovine serum (FBS) with penicillin, streptomycin, and am-
photericin B. Cells were maintained at 37°C in 5% CO2,
passaged before confluence, and fed twice weekly.
Wound assay. A linear wound assay was performed as
described previously.3 Briefly, rat VSMCs were grown to
confluence in 60-mm2 dishes and then starved for 24
hours, after which each dish was divided into a 2  3 grid.
A linear wound was made in each hemisphere of the dish by
using a pipette tip. Immediately after wounding, medium
was changed to fresh DMEM (for all reagent dishes and as
negative control) or 10% FBS (positive control). After the
determination of a dose-response curve (n  3 for control
and each concentration of S-1-P), 0.1 mol/L S-1-P (25
mg suspended in 5 mL methanol) was added to each dish
for all subsequent trials. Dishes were treated with S-1-P
either alone or with rapamycin (1 to 20 nmol/L). Trials
were performed with methanol (15 L) and dimethyl
sulfoxide (0.1%) as controls for S-1-P and rapamycin, re-
spectively. S-1-P did not induce DNA synthesis (as mea-
sured by 3H-thymidine incorporation) or cell proliferation
(as measured by manual cell counting during a 7-day
period) in these cells (data not shown). Under a 40 lens
with an attached SPOT camera (Diagnostic Instruments,
Inc, Sterling Heights, Mich), images were taken of the
intersections of the linear wound and each grid line, result-ing in eight fields per dish. Cells were allowed to migrate
during a period of 24 hours at 37°C. Each field was
photographed at time zero and after 24 hours. The area of
each field was measured by using SPOT Advanced soft-
ware, and eight fields from each dish were averaged. Trials
with each reagent or inhibitor were performed in at least six
separate dishes, and the results were averaged.
Boyden chamber assay. Chemotaxis was measured by
using a 48-well Boyden chamber (Neuroprobe Inc, Gaith-
ersburg, Md) and polycarbonate filters (10-m pore size,
25  80 mm, polyvinyl propylene free; Neuroprobe, Inc).
The filter was placed in sterile Dulbecco’s Phosphate-Buff-
ered Saline (dPBS) for 30 minutes before use. After the
determination of a dose-response curve for S-1-P, all sub-
sequent trials used 0.1 mol/L S-1-P in PBS in the lower
wells, with serum-free DMEM as negative and 10% FBS or
platelet-derived growth factor (PDGF) (10 ng /mL) as
positive controls. VSMCs at 60% to 70% confluence were
starved overnight in serum-free DMEM, trypsinized,
washed twice with dPBS, and resuspended in serum-free
DMEM at a concentration of 2 104 cells in 50 L. S-1-P
or control reagents were added to the lower wells, and the
polycarbonate membrane was placed over those wells. The
cell suspension was added to the upper wells in 50-L
aliquots. For trials with rapamycin (10 nmol/L), the inhib-
itor was added to 2 mL of the cell suspension 1 hour before
addition of cells to the upper wells. The chamber was
incubated at 37°C for 5 hours, and the membrane was then
removed. The cells on the upper side were scraped off, the
membrane was stained with Diff Quik (VWR Scientific
Products, Westchester, Pa), and the cells on the lower side
of the membrane were manually counted. Four high-power
fields (400) were counted per well and averaged. Trials
included eight or 12 wells per reagent or inhibitor per trial
and were repeated no fewer than three times.
Western blotting for p70S6K. VSMCs were grown
to 60% to 70% confluence in 100-mm2 plates and starved
for 24 hours in serum-free DMEM. Cells were stimulated
with 0.1 mol/L S-1-P alone or pretreated with inhibitors
of mTOR (rapamycin, 10 nmol/L), Gi (pertussis toxin,
100 ng/mL), PI3-K (wortmannin, 1 mol/L, and
LY294002, 10 mol/L), MEK1 (PD98059, 10 mol/L),
or p38MAPK (SB203580, 10 mol/L) for 1 hour before
stimulation with S-1-P. The doses and specificities of per-
tussis toxin, wortmannin, LY294002, PD98059, and
SB203580 have been detailed previously.3,4 Briefly, doses
were chosen at approximately the inhibitory concentration
of 50% for each inhibitor and have been used previously at
these doses. After stimulation (see Results for time points),
cells were washed with ice-cold PBS, harvested in ice-cold
mitogen-activated protein kinase (MAPK) lysis buffer
(50 mmol/L HEPES, 600 mmol/L NaCl, 3 mmol/L
MgCl2, 400 mmol/L ethylenediamine tetraacetic acid,
0.2% sodium dodecylsulfate, 1% Na deoxycholate, -
glycerophosphate, 2% Triton X-100, 1 mmol/L dithio-
threitol, 0.2 mmol/L sodium vanadate, 4 g/mL leupep-
tin, 0.2 mol/L phenylmethylsulfonyl fluoride, and 4
g/mL aprotinin, at pH 7.5), and sonicated. Samples were
ration
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electrophoresis (25 g of protein per well) and transferred
to nitrocellulose membranes. Blots were blocked for 1 hour
in Tris-buffered saline with 0.1% Tween 20 and 5% non-fat
dry milk for all antibodies. Blots were probed with antibod-
ies to phospho-p70S6K at Thr 421/Ser 424 (1:1000),
phospho-p70S6K at Thr 389 (1:1000), p70S6K (1:1000),
phospho-ERK1/2 (1:5000), or pan-ERK1/2 (1:5000)
Fig 1. A, Effect of rapamycin on S-1-P–induced migra
24 h in the presence of DMEM, S-1-P alone, or with r
wound area represents greater migration across an unco
decrease in wound area over six dishes (48 high-pow
S-1-P–induced migration in a Boyden chamber assay. SM
tion of 2  104 cells in 50 L per well and then allowe
during 4 h. Reagents in the bottom wells were DME
pretreated for 1 h with rapamycin (10 nmol/L), an inhib
counted manually, and 4 HPF per well were averaged.
(DMEM only) of at least three experiments of eight wells
for S-1-P alone. 10% serum resulted in two-fold the migat 4°C overnight. Blots were probed secondarily withperoxidase-conjugated anti-rabbit immunoglobulin G an-
tibody for phospho-ERK1/2, phospho-p70S6K (both
sites), and total p70S6K (Jackson, 1:10,000), or with
peroxidase-conjugated anti-mouse immunoglobulin G an-
tibody for total ERK1/2 (Biorad, 1:5000). Blots were then
visualized on x-ray film by using the Enhanced Chemo-
Luminescence (ECL) Western blotting detection system
(Amersham Pharmacia Biotech, Arlington Heights, Ill) for
in a wound assay. Cells were allowed to migrate during
ycin (1-10 nmol/L), or 10% FBS. A larger decrease in
culture dish. Values represent mean  sem of percent
elds [HPF]) per reagent. B, Effect of rapamycin on
ere washed and resuspended in DMEM at a concentra-
igrate through an uncoated polycarbonate membrane
1-P (5 mol/L), or 10% FBS. Cell suspensions were
of mTOR, in the S-1-P  Rapamycin group. Cells were
es represent mean  sem of fold increase over control
agent. Absolute cell numbers averaged 38 cells per HPF
of S-1-P alone (six-fold from control data not shown).tion
apam
ated
er fi
Cs w
d to m
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per reperoxidase activity. Band intensity was measured by using
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ments were performed at least three times.
Statistical analysis. All data are presented as the mean
 standard error of the mean (sem). Statistical differences
between groups were analyzed by using one-way analysis of
variance with post hoc Dunnett’s multiple comparisons
correction where appropriate. A P value of .05 was con-
sidered significant.
RESULTS
Rapamycin inhibits S-1-P–stimulated SMC migration.
S-1-P stimulated migration of VSMCs in both the linear
wound and Boyden microchemotaxis chamber assays two
to three times the level of control (P  .01 vs control for
Fig 2. A, Western blots of time courses of phosphorylat
upper time course represents phosphorylation at the Thr
lation at the Thr 421/Ser 424 site. The upper band in t
whereas the lower band represents p70S6K phosphoryla
Time 0 is an unstimulated control. Total p70S6K did no
all lanes (data not shown). B, Western blots of time course
1-h pretreatment with rapamycin (10 nmol/L), an inhi
p70S6K Thr 389 site (lower band of upper time course). B
is an unstimulated control without rapamycin pretreatm
and 10 min. Total p70S6K did not change at any time
shown). C, Time course of the phosphorylation of p70S6
first 60 minutes in response to S-1-P (5 mol/L). Value
over control (n  3).both, Fig 1, A and B). The doses of S-1-P used for eachassay were determined from previously published dose-
response curves.3,4 Rapamycin produced a concentration-
dependent decrease in cell migration with an inhibitory
concentration of 50% of 10 nmol/L (data not shown). The
presence of rapamycin inhibited migration in both assays to
the level of control (P  .01 vs S-1-P alone and P  not
significant vs control for both methods, Fig 1, A and B).
Serum-stimulated migration was approximately twice the
level of S-1-P for both assays (Fig 1, A and data not shown).
S-1-P stimulates mTOR-dependent p70S6K phos-
phorylation. Phosphorylation of p70S6K was used as a
downstream readout of mTOR activity. p70S6K is phos-
phorylated at multiple sites after growth factor or amino
acid stimulation8 and requires mTOR activity for full acti-
S6 kinase 1 after treatment with S-1-P (5mol/L). The
ite, whereas the lower time course represents phosphory-
r 389 time course represents p85S6K phosphorylation,
Blots are representative of three separate experiments.
nge at any time point, and protein loading was equal for
hosphorylation of S6 kinase 1 by S-1-P (5mol/L) after
of mTOR. There is complete dephosphorylation of the
are representative of three separate experiments. Time 0
1P 5 and S1P 10 are positive controls (S-1-P alone) at 5
t, and protein loading was equal for all lanes (data not
r 389 site and p70S6K Thr 421/Ser 424 site during the
resent the mean  sem fold increase of phosphorylationion of
389 s
he Th
tion.
t cha
s of p
bitor
lots
ent. S
poin
K Th
s repvation. In addition, S6 kinase I exists as both p70 and p85
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p85 is exclusively nuclear.8 The function of the p85 form is
less clear, and it seems more likely that the p70 form is
involved in the migration response. Two phosphorylation
sites were selected: Thr 389, a site in the linker domain, and
Thr 421/Ser 424, a site in the carboxy-terminal auto-
inhibitory domain. The phosphorylation state of the Thr
389 site has been found to correlate with p70S6K enzyme
activity, and this site is the most rapamycin-sensitive. The
Thr 421/Ser 424 site might be growth factor– or MAPK-
regulated, and its phosphorylation is necessary for relief of
Fig 3. A, Western blots of time courses of S6 kinase 1 p
with wortmannin (1mol/L), an inhibitor of PI3-K. Th
(lower band of upper time course). Total p70S6K did not c
lanes (data not shown). Blots are representative of thr
without rapamycin pretreatment. S1P 5 and S1P 10 are po
of time courses of S6 kinase 1 phosphorylation by S-1
mol/L), an inhibitor of PI3-K. There is complete depho
time course). Total p70S6K did not change at any time
shown). Blots are representative of three separate experi
pretreatment. S1P 5 and S1P 10 are positive controls
(LY294002 alone at 5 min). C, Phosphorylation of p70S
and 10 min, right) sites with S-1-P alone (5 mol/L)
LY294002 (10 mol/L). Total p70S6K did not change
(data not shown). Values represent mean sem of fold in
experiments. *P  .01 vs S-1-P alone.auto-inhibition and exposure of other catalytic sites. S-1-Pstimulated phosphorylation of both sites in a time-depen-
dent manner (Fig 2,A andC). Rapamycin pretreatment for
1 hour led to complete dephosphorylation of p70S6K at
the Thr 389 site, even after stimulation with S-1-P, but it
had no effect on the analogous site for p85 or the Thr
421/Ser 424 site (Fig 2, B). These data suggest that
mTOR activity is necessary for p70S6K phosphorylation at
the Thr 389 site, and that this regulation is specific to
p70S6K after 1 hour pretreatment with rapamycin.
PI3-K regulates p70S6K phosphorylation by
S-1-P. We have demonstrated previously that inhibition of
horylation by S-1-P (5 mol/L) after 1-h pretreatment
complete dephosphorylation of the p70S6K Thr 389 site
e at any time point, and protein loading was equal for all
arate experiments. Time 0 is an unstimulated control
controls (S-1-P alone) at 5 and 10 min. B, Western blots
mol/L) after 1-h pretreatment with LY294002 (10
rylation of the p70S6K Thr 389 site (lower band of upper
t, and protein loading was equal for all lanes (data not
s. Time 0 is an unstimulated control without rapamycin
P alone) at 5 and 10 min. LY 5 is a negative control
t Thr 389 (5 and 10 min, left) and Thr 421/Ser 424 (5
ter 1-h pretreatment with wortmannin (1 mol/L) or
y time point, and protein loading was equal for all lanes
e over control and represent the results of three separatehosp
ere is
hang
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-P (5
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phosphorylation.4 Similar to rapamycin, pretreatment with
wortmannin and LY294002 resulted in complete dephos-
phorylation of p70S6K, even after S-1-P addition (Fig 3,
A-C). There was no effect on p85 phosphorylation or on
the Thr 421/Ser 424 site. These results suggest that PI3-K
activity is necessary for p70S6K phosphorylation at the Thr
389 site, and that this regulation is specific to p70S6K (as
with rapamycin). Akt is one of the downstream kinases
linked to PI3-K and is considered to modulate S6K in some
cells. Incubation with Akt inhibitors blocked Akt phos-
phorylation (data not shown) but had no effect on S6K
phosphorylation at the Thr 389 site. These data support a
role for Akt independent activation of mTOR/p70S6K in
response to S-1-P (see schema Fig 4).
MEK1/2 but not p38MAPK might regulate p70S6K
phosphorylation by S-1-P. We have previously shown
that S-1-P stimulates SMC migration that is inhibited by
PD98059 and SB203580 (inhibitors of MEK1 and acti-
vated p38MAPK, respectively).3,4 Pretreatment with rapa-
mycin does affect ERK1/2 phosphorylation at 10, 15, and
20 minutes (Fig 5, A) but does not affect p38MAPK phos-
phorylation by S-1-P at any time point (data not shown).
This must suggest that the effects of rapamycin on migra-
tion might in part be due to inhibition of ERK1/2 kinases.
SB203580 pretreatment had no effect on S-1-P–induced
phosphorylation of either phosphorylation site on p70S6K
(Fig 5, B and D). Pretreatment with PD98059 did reduce
Fig 4. S-1-P and mTOR: S-1-P activates the EDG-1 and
MAPK pathways ERK1/2 and p38MAPK are activated a
phosphorylation of ERK1/2, PDK1, and Akt. mTOR
leading to a decrease in p70S6K activation. This report
and that there appears to be Akt-independent activation
pathway. Inhibition of mTOR by rapamycin results in thphosphorylation of p70S6K at the Thr 389 and Thr 421/Ser 424 sites (Fig 5, C and D), suggesting that MEK1 does
regulate p70S6K phosphorylation (see schema Fig 4).
DISCUSSION
Cell migration is a complex program that allows a cell
to move through tissue and is a principal process in wound
healing. Both transcription and translation are required to
provide the proteins necessary to achieve migration. Con-
trol of translation is mediated by the influence of mTOR on
the activity of p70S6K, which regulates many key cell cycle
and nuclear events involved in cell growth and function.9-11
mTOR is regulated by the TSC1/TSC2 complex12 and can
be inhibited by rapamycin. Rapamycin has been shown to
block both SMC proliferation and migration in response to
serum, basic fibroblast growth factor (bFGF),13 and
PDGF.14 The association of mTOR/p70S6K with the
cytoskeleton is tentative, but it does appear that rapamycin
can also prevent Ca2 associated stress fiber formation,15
and that p70S6K can be co-localized with actin stress fibers
near the forward edge of migrating cells.16 Insertion of
hamartin, a protein that inhibits mTOR activity, will inter-
rupt p70S6K signaling and block cell migration.17 Com-
petitive displacement of rapamycin with FK406 prevents
the inhibition of rapamycin on cell migration.18 Collec-
tively, these data suggest a role for mTOR-regulated
p70S6K in cell migration.
We have demonstrated that S-1-P stimulates migration
that is inhibited completely by rapamycin pretreatment in a
ceptors on SMCs, leading to activation of a Gi protein.
ad to cell migration. PI3-K is also activated, leading to
stream of P70S6K and can be inhibited by rapamycin,
sts that p70S6K is downstream of PI3-K and MEK1/2
0S6K. There is crosstalk with mTOR and the ERK1/2
ibition of cell migration in response to S-1-P.-3 re
nd le
is up
sugge
of p7concentration-dependent manner. With pharmacologic in-
.05
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p70S6K through mTOR- and PI3-K–dependent mecha-
nisms, and that the MAP kinases ERK1/2 and p38MAPK,
which independently regulate SMC migration stimulated
by S-1-P,3,4 do not appear to regulate p70S6K phosphor-
ylation. Whereas S-1-P stimulates phosphorylation of
p70S6K at both Thr 389 and Thr 421/Ser 424 sites, only
the Thr 389 site is regulated by mTOR and PI3-K. Phos-
phorylation of the p85 form of the protein, which is exclu-
sively nuclear,9 at the site corresponding to Thr 389 on
p70S6K is not affected by rapamycin. In contrast to several
reports, we did not find a role for Akt in the activation of
p70S6K.19 Recent data suggest that the tuberous sclerosis
gene products (TSC1 and TSC2) interact in a functional
Fig 5. A, Western blots of time courses of ERK1/2
pretreatment with rapamycin (10 nmol/L). Blots are rep
were significant differences between the rapamycin-treate
no change in total ERK1/2 at any time point, and prote
an unstimulated control. B, Western blots of time course
1-h pretreatment with SB203580 (10 mol/L), an inhi
any time point, and protein loading was equal for all lan
three separate experiments. Time 0 is an unstimulated co
at 5 min (positive control), and SB 5 is SB203580 alone (n
of time courses of S6 kinase 1 phosphorylation with S-
mol/L), an inhibitor of MEK1. Total p70S6K did not c
lanes (data not shown). Blots are representative of the re
control without PD98059 pretreatment. S1P 5 and S1P
is PD98059 alone (negative control) in the Thr 389 time
min, left) and Thr 421/Ser 424 (5 and 10 min, right) site
PD98059 (10 mol/L) or SB203580 (10 mol/L). Va
represent the results of three separate experiments. *P complex that might represent the connection between thePI3-K/Akt/PDK and mTOR pathways in both Drosophila
and mammalian cells.20 Those experiments also empha-
sized the specific regulation of the Thr 389 site by mTOR
and PI3-K pathways.
Recent reports showed inhibition of migration stimu-
lated by bFGF in mouse aortic SMCs13 and by PDGF-BB
in rat and human SMCs14 after 48 hours of rapamycin
pretreatment. However, both studies found no effect with
rapamycin pretreatment up to 6 hours. The long pretreat-
ment in both studies might have altered the proportion of
cells in G1/S phases that might be more prone to migrate
after stimulation; rapamycin might not specifically antago-
nize migration in response to these agonists. Differences
from our findings might be due to the fact that PDGF and
phorylation by S-1-P alone (5 mol/L) or after 1-h
tative of the results of three separate experiments; there
untreated groups at 10, 15, and 20 minutes. There was
ding was equal for all lanes (data not shown). Time 0 is
6 kinase 1 phosphorylation with S-1-P (5 mol/L) after
of activated p38MAPK. Total p70S6K did not change at
ta not shown). Blots are representative of the results of
l without SB203580 pretreatment. S1P 5 is S-1-P alone
ive control) in the Thr 389 time course. C, Western blots
5 mol/L) after 1-h pretreatment with PD98059 (10
e at any time point, and protein loading was equal for all
f three separate experiments. Time 0 is an unstimulated
e S-1-P alone at 5 and 10 min (positive controls); PD 5
se. D, Phosphorylation of p70S6K at Thr 389 (5 and 10
S-1-P alone (5 mol/L) or after 1-h pretreatment with
represent mean  sem of fold increase over control and
vs S-1-P alone.phos
resen
d and
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ways might negate the effects of inhibition of mTOR alone
with these agonists. In addition, S-1-P receptors initially
couple exclusively to G-proteins, whereas PDGF and bFGF
stimulate tyrosine kinase receptors specifically (although
receptor transactivation likely occurs). Kluk and Hla5 re-
ported no effect of rapamycin pretreatment on migration of
their rat SMCs after S-1-P stimulation, but in contrast to
our SMCs,4 their adult cells expressed very little S-1-P1,
and S-1-P only stimulated migration after transfection of
S-1-P1 in their model. Although the link between PDGF
and S-1-P in migration has already been established,6 a
more recent report has suggested that S-1-P can potently
stimulate PDGF-A and PDGF-B chain expression through
both ERK1/2 and p38MAPK pathways’ activation of AP-
1.21 It is possible that mTOR/p70S6K is involved in the
translation of the PDGF-A and B chains, and this would
contribute to long-term migration in response to S-1-P.
Although such a mechanism would be involved in the
wound assay in these experiments, the short duration of the
Boyden chamber is likely insufficient for this mechanism to
contribute to the migration response.
A novel finding is that rapamycin inhibited ERK1/2
activation. This appears not to be a nonspecific effect,
because neither p38MAPK nor Akt was not inhibited by
rapamycin. This crosstalk has been identified recently in
VSMCs by others.22 How this crosstalk between the
ERK1/2 pathway and mTOR/p70S6K might occur is as
yet not defined. Inhibition of p38MAPK with SB203580
had no significant effect on p70S6K phosphorylation at
either site tested. Pretreatment with PD98059, a MEK1
inhibitor, did reduce phosphorylation of p70S6K at the Thr
389 and Thr 421/Ser 424 sites, suggesting that MEK1
might partially regulate p70S6K phosphorylation. It has
been shown in cell lines that phosphorylation and inactiva-
tion of TSC2 can occur through a PI3-K–dependent but
Akt-independent pathway that involves either protein ki-
nase C– or MEK-mediated mechanisms.23 Although some
evidence suggests that the Thr 421/Ser 424 site is growth
factor–regulated,8,24 the current Western blotting data
show no reduction in phosphorylation at this site with
inhibition of mTOR, PI3-K, Akt, ERK1/2, or p38MAPK
before S-1-P treatment.
In conclusion, S-1-P–mediated cell migration requires
ribosomal p70S6 kinase through a PI3-K–dependent man-
ner, Akt independent, and involves mTOR. This mecha-
nism likely involves modulation of the ERK1/2 pathway
(see schema Fig 4). S-1-P is released from activated platelets
at sites of injury and is also a secondary mediator of PDGF
on SMCs. The effect of rapamycin on S-1-P signaling adds
another facet to mechanisms in vivo, whereby rapamycin
might interfere with the response to injury after vascular
intervention.
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